Immunic is a biotechnology company developing oral drugs for multiple sclerosis and gastrointestinal diseases. IMUX reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 10 | Wedbush | Reiterated | Buy | |
| Aug 17 | Wedbush | Initiated | Buy | |
| May 22 | B. Riley Securities | Maintained | Buy | |
| Apr 17 | Stifel | Initiated | Buy |
Seasonality
How IMUX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in IMUX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMUX is in one of them and how their past IMUX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMUX in an article yet. Here's the latest on the wider market.
About Immunic
Immunic is a biotechnology company that develops oral drugs for neurologic and gastrointestinal diseases. Its lead candidate, vidofludimus calcium, is in Phase 3 testing for relapsing multiple sclerosis, and its IMU-856 candidate is being developed for conditions such as celiac disease and inflammatory bowel disease. The company has no products approved for sale yet and has not generated revenue from product sales. It is headquartered in New York, with its main research operations in Germany.
- Headquarters
- New York